Saturday 17 October 2026
Export CERS’s income statement to Excel — free account
Cerus Corporation
CERS Healthcare Medical Devices
In the quarter to June 2026, revenue grew 5.28%, EPS grew 50.3%, free cash flow fell 20.9% and total debt fell 23.5%, each against the same quarter a year earlier.
2.20
0.06
−2.65%
Follow CERS
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
1.35 | 1.68 | 1.44 | 2.36 | |
P/FCF ratio |
1,815.53 | 354.35 | 0.00 | 0.00 | |
P/Operating CF |
158.28 | 63.33 | (115.89) | (220.09) | |
P/B ratio |
4.90 | 6.04 | 5.17 | 8.28 | |
Price to Tangible BV |
5.01 | 6.17 | 5.28 | 8.44 | |
EV/Sales |
1.38 | 1.68 | 1.46 | 2.40 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 9,004.57 | |
EV/Operating CF |
87.33 | 81.38 | 135.92 | 245.88 | |
EV/FCF |
1,853.58 | 355.26 | (293.71) | (324.93) | |
Quick Ratio |
1.22 | 1.12 | 1.02 | 1.02 | |
Current Ratio |
1.89 | 1.73 | 1.63 | 1.83 | |
Net Debt/EBITDA |
3.95 | (4.07) | 47.38 | (6.19) | |
Debt/Assets |
39.46% | 37.81% | 38.06% | 31.64% | |
Debt/Equity |
1.36 | 1.29 | 1.24 | 0.92 | |
Asset Turnover |
1.12 | 1.11 | 1.14 | 1.19 | |
Operating CF/Net income |
(101.42) | (2.84) | 1.86 | 0.91 | |
Capex/Depreciation |
(4.80) | (3.33) | (0.52) | (1.89) | |
Interest Coverage |
0.58 | (0.33) | (0.19) | (1.08) | |
Research and Development Expense of Revenue |
26.27% | 25.38% | 24.26% | 22.73% | |
Selling, General and Administrative Expense of Revenue |
30.91% | 32.25% | 33.31% | 36.12% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
9.34% | 7.63% | 8.19% | 8.68% | |
Graham Net Nets |
0.05 | 0.04 | 0.06 | 0.04 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(5.25%) | (3.89%) | (2.75%) | (1.20%) | |
Free Cash Flow Yield |
0.06% | 0.28% | (0.34%) | (0.31%) | |
Revenue per Share |
0.31 | 0.34 | 0.31 | 0.32 | |
Operating CF per Share |
0.01 | 0.03 | (0.02) | (0.01) | |
Capex per Share |
(0.01) | (0.01) | 0.00 | 0.00 | |
Free Cash Flow per Share |
0.00 | 0.03 | (0.02) | (0.02) | |
Cash per Share |
0.41 | 0.43 | 0.41 | 0.28 | |
Shareholders Equity per Share |
0.32 | 0.34 | 0.35 | 0.35 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.32 | 0.34 | 0.35 | 0.35 | |
Free Cash Flow |
0.09 | 4.89 | (3.28) | (3.53) | |
Working Capital |
78.69 | 73.58 | 67.96 | 71.52 | |
Capital Expenditures |
(1.83) | (1.31) | (0.23) | (0.87) | |
Net Current Asset Value |
14.15 | 17.49 | 20.72 | 22.84 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.03 | 0.02 | 0.00 | 0.01 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
27.07 | 30.08 | 27.83 | 31.18 | |
Average Payables |
20.67 | 24.85 | 29.73 | 32.02 | |
Average Inventory |
44.84 | 47.13 | 54.64 | 60.17 | |
Average Assets |
202.36 | 211.39 | 214.84 | 209.13 | |
Average Common Equity |
58.24 | 60.93 | 62.26 | 63.44 |
Columns are period end dates